clinical practice guidelinesBone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cited by (0)
Approved by the ESMO Guidelines Working Group: March 2010.
Prof. Paulussen's affiliation will change as of July 2010 to: Vestische Kinder- und Jugendklinik Datteln, University of Witten/Herdecke, Germany.
Conflict of interest: Dr Athanasou has reported no conflicts of interest; Prof. Bielack has reported that he is a consultant for IDM, Roche and Takeda Millenium and that he is on the advisory board for Merck; Prof. De Alava has reported no conflicts of interest; Dr Dei Tos has reported no conflicts of interest; Dr Ferrari has reported that he is a consultant for Takeda and that he is conducting research sponsored by Pfizer, Roche and Amgen; Dr Gelderblom has reported no conflicts of interest; Dr Grimer has reported no conflicts of interest; Dr Hall has reported no conflicts of interest; Prof. Hassan has reported that at present he has no conflicts of interest, but he is planning trials with Takeda and Pharmamar; Prof. Hogendoorn has reported no conflicts of interest; Prof. Jurgens has reported no conflicts of interest; Prof. Paulussen has reported no conflicts of interest; Dr Rozeman has reported no conflicts of interest; Prof. Taminiau has reported no conflicts of interest; Dr Whelan has reported no conflicts of interest; Dr Vanel has reported no conflicts of interest.